$NTLA News
Last published 2d ago
- 2d agoNTLAIntellia Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoNTLAIntellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026GlobeNewswireCAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced highlights from its seven presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. ...
- 4d agoNTLAIntellia Therapeutics to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswireCAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 at 8:30 a.m. GMT / 3:30 a.m. ET.
- 1w agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 1w agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on...
- 1w agoNTLAIntellia Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoNTLAIntellia Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswireOn track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple
- 1w agoNTLAIntellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)GlobeNewswireCAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 1w agoNTLAIntellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress PresentationsGlobeNewswirePresentation at AHA on Nov. 9 to highlight cardiac outcomes following a single dose of nex-z in patients with ATTRv-PN with mixed phenotype from the Phase 1 clinical trial Presentation at ISA on Nov. 18 to include up to
- 2w agoNTLAIntellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026GlobeNewswireOral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals Poster presentations to include
- 2w agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 1mo agoNTLAIntellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical OfficerGlobeNewswireCAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 2mo agoNTLAIntellia Therapeutics - 1773662 - INTELLIA THERAPEUTICS INCEarnings Call TranscriptsAll right. Well, thanks, everyone, for joining us. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.co
- 2mo agoNTLAMorgan Stanley 24th Annual Global Healthcare Conference - INTELLIA THERAPEUTICS INCEarnings Call TranscriptsAll right. Well, thanks, everyone, for joining us. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.co
- 2mo agoNTLAIntellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)GlobeNewswireFDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., Sept.
- 2mo agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 2mo agoNTLAIntellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 MillionGlobeNewswireCAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 2mo agoNTLAIntellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 3mo agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 3mo agoNTLAIntellia Therapeutics Second Quarter 2026 Earnings Conference Call - INTELLIA THERAPEUTICS INCEarnings Call TranscriptsHello, and welcome to Intelia Therapeutics' second quarter conference call. My name is Chloe, and I will be your conference operator today. Please be advised that today's call is being recorded. I would now like to turn
- 3mo agoNTLAIntellia Therapeutics Second Quarter 2026 Earnings Conference Call - INTELLIA THERAPEUTICS INCEarnings Call TranscriptsHello, and welcome to Intelia Therapeutics' second quarter conference call. My name is Chloe, and I will be your conference operator today. Please be advised that today's call is being recorded. I would now like to turn
- 3mo agoNTLAIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesGlobeNewswirePositive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first
- 3mo agoNTLAIntellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business UpdatesGlobeNewswireCAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 4mo agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 5mo agoNTLAIntellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaGlobeNewswireData from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New
- 5mo agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 5mo agoNTLAJefferies Global Healthcare Conference in New York - INTELLIA THERAPEUTICS INCEarnings Call TranscriptsHi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to introduce and welcome John Leonard, the CEO of Intelia. We're doing fireside chat format, so thanks for joining us t
- 5mo agoNTLAIntellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026GlobeNewswireCAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 6mo agoNTLAIntellia Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesGlobeNewswirePresented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2
- 6mo agoNTLAIntellia Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 6mo agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 6mo agoNTLAIntellia Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 6mo agoNTLAIntellia Announces Proposed Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 6mo agoNTLAIntellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary AngioedemaGlobeNewswireCAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 6mo agoNTLAIntellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene EditingGlobeNewswirePhase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing
- 6mo agoNTLAIntellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026GlobeNewswireWorld's first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia
- 7mo agoANVSARQTAVAINTLA+1The Credibility Filter Wall Street Uses to Sort Biotech WinnersGlobeNewswireVANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid
- 7mo agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 8mo agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 8mo agoGERNNTLANAGEOCGNInvestors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B MilestonePR NewswireMarket News Updates News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look for...
- 8mo agoNTLAIntellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026GlobeNewswireCAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 8mo agoNTLAIntellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CMGlobeNewswireCAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core
- 8mo agoNTLAIntellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business UpdatesGlobeNewswireHAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for MAGNITUDE-2 Phase 3
- 8mo agoNTLAIntellia Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today
- 8mo agoNTLAIntellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business UpdatesGlobeNewswireCAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today
- 9mo agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today
- 9mo agoCRSPEDITKBLBNTLACutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and MedicineGlobeNewswireDENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic diseases,
- 9mo agoNTLAIntellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PNGlobeNewswirePlan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia
- 10mo agoNTLAIntellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today
- 10mo agoNTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today